After experiencing an acute coronary syndrome (ACS), patients are at a high risk of suffering
from recurrent ischaemic cardiovascular events, especially in the very early phase. Low …

The objective of this scientific statement is to evaluate contemporary evidence that either
supports or refutes the conclusion that aggressive low-density lipoprotein cholesterol …

Background: VERVE-101 is an investigational in vivo CRISPR base-editing medicine
designed to alter a single DNA base in the PCSK9 gene, permanently turn off hepatic …

Global guidelines for the management of high-cardiovascular-risk patients include
aggressive goals for low-density lipoprotein cholesterol (LDL-C). Statin therapy alone is …

Background MK-0616 is an oral macrocyclic peptide inhibitor of proprotein convertase
subtilisin/kexin type 9 (PCSK9) in development for the treatment of hypercholesterolemia …

Background Most patients with atherosclerotic cardiovascular disease fail to achieve
guideline-directed low-density lipoprotein cholesterol (LDL-C) goals. Twice-yearly inclisiran …

Abstract Purpose of Review To discuss the history of cardiovascular outcomes trials of
cholesteryl ester transfer protein (CETP) inhibitors and to describe obicetrapib, a next …

Background Preventive therapy among patients with established atherosclerotic
cardiovascular disease (ASCVD) is generally underused. Whether new guideline …

The pharmacological treatment of dyslipidemia, a major modifiable risk factor for develo**
atherosclerotic cardiovascular disease (ASCVD), remains a debated and controversial …

Objective Dyslipidemia is one of the major public health problems in China. It is
characterized by multisystem dysregulation and inflammation, and oxidant/antioxidant …